Artelon, Inc. Secures $20M in Funding to Advance Surgical Treatment of Joint Instability
Summary
The financing will fund commercial growth, clinical research, and expansion of Artelons product line for surgical treatment of ankles and other joints. "Ankle sprains are the number one reason for emergency room visits in the United States, and up to 20 percent of those patients will develop chronic instability after these injuries. Artelons innovative surgical solutions represent more than 30 years of research and expertise on the complex interaction of mechanics and biology in tendon and ligament reconstruction. "Following on the commercial success of our current Flexband\xae SOLO and Flexband MULTI products, this funding will allow us to take on adjacent clinical indications and pursue leadership within the $2B U.S. ankle instability market, while expanding our efforts to address latent customer needs in other unstable joints. ""Artelon is focused on bringing value to patients and healthcare providers through a platform that enhances soft tissue repair while restoring stability and motion," said Greg Banker of Vensana Capital.